Published in Anticancer Drugs on August 01, 2002
Drug development from marine natural products. Nat Rev Drug Discov (2008) 4.08
The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line. Biochem Pharmacol (2011) 1.01
Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol Psychiatry (2015) 0.93
Marine-derived angiogenesis inhibitors for cancer therapy. Mar Drugs (2013) 0.89
Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. J Biol Chem (2010) 0.84
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br J Cancer (2003) 0.82
Euphohelioscopin A is a PKC activator capable of inducing macrophage differentiation. Chem Biol (2012) 0.79
Bryostatin-1, Fenretinide and 1α,25 (OH)(2)D(3) Induce Growth Inhibition, Apoptosis and Differentiation in T and B Cell-Derived Acute Lymphoblastic Leukemia Cell Lines (CCRF-CEM and Nalm-6). Avicenna J Med Biotechnol (2011) 0.79
Total synthesis of bryostatins: the development of methodology for the atom-economic and stereoselective synthesis of the ring C subunit. Chemistry (2011) 0.76
Synthesis and Cytotoxicity against K562 Cells of 3-O-Angeloyl-20-O-acetyl Ingenol, a Derivative of Ingenol Mebutate. Int J Mol Sci (2016) 0.75
In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. PLoS Pathog (2017) 0.75
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer (2007) 2.98
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer (2009) 1.78
Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75
Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol (2003) 1.61
Intra-tumoural microvessel density in human solid tumours. Br J Cancer (2002) 1.60
Carcinosarcoma of the ovary. Br J Cancer (2003) 1.41
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer (2011) 1.40
The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) (2003) 1.23
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol (2000) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. Br J Cancer (2000) 1.08
Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis (2007) 1.06
Antiangiogenic drugs in ovarian cancer. Br J Cancer (2008) 1.06
Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer (2003) 1.00
Quantitative angiogenesis assays in vivo--a review. Angiogenesis (2004) 0.99
Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer (2005) 0.98
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol (2010) 0.97
Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer (2007) 0.97
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol (2010) 0.93
The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer (2005) 0.92
p53 and related proteins in epithelial ovarian cancer. Eur J Cancer (2000) 0.88
The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer (1998) 0.88
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 0.88
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol (2010) 0.87
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res (2007) 0.87
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer (2001) 0.86
An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. Br J Cancer (1999) 0.85
VEGF antagonists. Expert Opin Biol Ther (2001) 0.83
Resistance to anti-VEGF agents. Curr Pharm Des (2004) 0.82
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br J Cancer (2003) 0.82
Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer. Clin Oncol (R Coll Radiol) (2005) 0.81
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Ann Oncol (2000) 0.79
Weekly paclitaxel in the treatment of recurrent ovarian carcinoma. Eur J Gynaecol Oncol (2007) 0.79
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer (2006) 0.78
Cross-visit tumor sub-segmentation and registration with outlier rejection for dynamic contrast-enhanced MRI time series data. Med Image Comput Comput Assist Interv (2010) 0.77
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol (2007) 0.77
Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol (2000) 0.77
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer (2010) 0.77
The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol (2006) 0.77
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. Anticancer Res (2005) 0.76
Weekly platinum chemotherapy for recurrent ovarian cancer. Br J Cancer (2002) 0.75
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecol Oncol (2004) 0.75
Oral melphalan as a treatment for platinum-resistant ovarian cancer. Br J Cancer (2003) 0.75
Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. J Cancer Res Clin Oncol (2005) 0.75
The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. Clin Oncol (R Coll Radiol) (2007) 0.75
Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer (2006) 0.75